Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14805638 | 0.80 | SRC (0.42) | ARHPGDIMPDH2 | |
| SCHEMBL10323392 | 0.71 | HPGD (0.45) | HPGDIMPDH2GPR35 | |
| SCHEMBL10322938 | 0.70 | HPGD (0.41) | HPGDIMPDH2NPC1RAB9AGPR35 | |
| SCHEMBL10323334 | 0.70 | GAA (0.40) | HPGDIMPDH2HSD17B10GPR35 | |
| SCHEMBL16122429 | 0.70 | AR (0.33) | ARPGR | |
| SCHEMBL14805868 | 0.68 | ALDH1A1 (0.54) | ARIMPDH2NPC1RAB9ATP53 | |
| SCHEMBL25328775 | 0.68 | GABRA1 (0.46) | — | |
| SCHEMBL13652097 | 0.67 | NOS2 (0.51) | ARHPGDNPC1RAB9ATP53 | |
| SCHEMBL21780744 | 0.67 | NPC1 (0.47) | ARNPC1RAB9ATP53HSD17B10 | |
| SCHEMBL20231243 | 0.67 | TSHR (0.42) | ARIMPDH2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | AR 2395/4885HPGD 1233/4885IMPDH2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.